Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.

Item
http://www.wikidata.org/entity/Q43110557
Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatmentDecreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)Zoledronic acid: multiplicity of use across the cancer continuum.Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.Antiresorptive treatment-associated ONJ.
P2860

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.

Item
http://www.wikidata.org/entity/Q43110557
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Osteonecrosis of the jaw (ONJ) ...... ter zoledronic acid treatment.
@en
type
label
Osteonecrosis of the jaw (ONJ) ...... ter zoledronic acid treatment.
@en
prefLabel
Osteonecrosis of the jaw (ONJ) ...... ter zoledronic acid treatment.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Osteonecrosis of the jaw (ONJ) ...... fter zoledronic acid treatment
@en
P2093
P304
P31
P356
10.1016/J.BREAST.2010.03.008
P433
P478
P50
P577
P698